The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
million at-the-market follow-on equity offering and a US$392.14 million shelf registration tied to employee stock plans. Alongside these financing moves, Kymera appointed experienced drug developer Dr. Neil Graham as Chief Development Officer, underscoring its commitment to advancing its emerging oral immunology pipeline despite widening losses. We'll now examine how Kymera's larger losses, fresh equity plans, and CDO hire reshape its investment narrative and risk profile. We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. Kymera Therapeutics Investment Narrative Recap To own Kymera today, you have to believe its oral protein degraders, especially STAT6 and IRF5, can translate into successful late stage trials and eventual commercial products despite ongoing heavy losses. The latest results increase near term financial risk, but do not materially change the key near term catalyst: clinical progress and data from
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 144
- 3/4/26 - Form 4
- KYMR's page on the SEC website